Company Overview
Snapshot
Founded in January 2022 by Moshe Elkabets and Angel Porgador, ImmuniQ operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on customer development for its personalized immuno-oncology treatment solutions.
Business overview
ImmuniQ is a Health Tech & Life Sciences company specializing in personalized immuno-oncology treatments. The company has developed a proprietary immune checkpoint artificial reporter (IcAR) technology designed to quantify the functional tumor response to immunotherapy drugs. This technology measures the actual surface activity of a patient’s cancer cells, aiming to enable more effective and tailored treatment strategies for individuals. ImmuniQ operates within the pharmaceuticals, drug discovery, and immunology sectors, serving the healthcare and life sciences markets.
Log in to access full profile ›Company Intelligence Q&A
- What is ImmuniQ's primary focus?
- ImmuniQ focuses on personalized immuno-oncology treatment, developing methods to quantify tumor response to immunotherapy drugs for more effective patient care.
- When was ImmuniQ founded?
- ImmuniQ was founded in January 2022.
- Who are the founders of ImmuniQ?
- ImmuniQ was co-founded by Moshe Elkabets and Angel Porgador.
- What is ImmuniQ's core technology?
- ImmuniQ's core technology is the immune checkpoint artificial reporter (IcAR), which quantifies binding and surface activity of patient cancer cells to assess functional tumor response to immunotherapy.
- In which sectors does ImmuniQ operate?
- ImmuniQ operates in the Health Tech & Life Sciences sector, specifically within pharmaceuticals, drug discovery, immunology, and cancer.